BIOGEN INC. - COMMON STOCK

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

30 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

30 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

29 Mar 2023 07:45:00 By Nasdaq GlobeNewswire

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

22 Mar 2023 19:32:40 By Nasdaq GlobeNewswire

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

16 Mar 2023 05:30:14 By Nasdaq GlobeNewswire

Biogen Appoints Chuck Triano as Head of Investor Relations

14 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

08 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

05 Mar 2023 17:30:00 By Nasdaq GlobeNewswire

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

27 Feb 2023 17:30:00 By Nasdaq GlobeNewswire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

06 Feb 2023 05:30:00 By Nasdaq GlobeNewswire

Lecanemab Receives Priority Review Status in Japan

29 Jan 2023 17:30:00 By Nasdaq GlobeNewswire

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

26 Jan 2023 17:30:00 By Nasdaq GlobeNewswire

Biogen Names Priya Singhal as Executive Vice President, Head of Development

05 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

04 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration

19 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

09 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

05 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Biogen Names Christopher Viehbacher President and Chief Executive Officer

10 Nov 2022 06:30:01 By Nasdaq GlobeNewswire

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

26 Oct 2022 05:05:00 By Nasdaq GlobeNewswire

New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS

26 Oct 2022 05:02:00 By Nasdaq GlobeNewswire